On Jan. 6, 2021, Bayer announced it had signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA).

Bayer supported the further development, supply and key territory operations of CureVacﾴs COVID-19 vaccine candidate CVnCoV and will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries.. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVacﾴs COVID-19 vaccine candidate CVnCoV.